AbbVie Closes $10.9B Apogee Deal, Adding Long-Acting Eczema Drug

Media partner

POLICY & MARKETS · IMMUNOLOGY & INFLAMMATION · SEPTEMBER 12, 2026 · UNITED STATES

Completed on the terms announced in June, AbbVie’s $10.9 billion all-cash acquisition of Apogee Therapeutics — a Boston-area clinical-stage biotechnology company — closed in the third quarter of 2026, per a company statement. The deal, priced at $135.11 per share and representing a 49% premium to Apogee’s last closing price, according to BioPharma Dive, is AbbVie’s largest since its $63 billion purchase of Allergan in 2019 and surpasses its $10.1 billion ImmunoGen buyout in 2023.

The strategic logic is straightforward: AbbVie is acquiring a direct competitor to Dupixent, Sanofi and Regeneron’s blockbuster antibody for atopic dermatitis (eczema) and asthma, at a moment when its own legacy immunology anchor, Humira, has been reduced to a residual revenue line. Humira generated $4.5 billion in 2025 sales, down sharply from its peak, while Skyrizi and Rinvoq — the drugs that replaced it — produced $17.5 billion and $8.3 billion respectively, helping AbbVie reach a record $61.1 billion in total 2025 revenues, according to Fierce Pharma. That record was achieved despite nearly $16 billion in cumulative U.S. Humira erosion since biosimilar entry, per AbbVie chief executive Robert Michael on the company’s fourth-quarter earnings call.

Zumilokibart’s dosing edge — and what it does not yet prove

Apogee’s lead asset, zumilokibart, is an interleukin-13 (IL-13) antibody being developed for atopic dermatitis and asthma. Its proposed clinical differentiation rests on dosing frequency: where Dupixent requires an injection every two weeks, zumilokibart is being developed for two to four injections per year, according to BioPharma Dive. AbbVie has described the drug’s commercial potential as ‘mega-blockbuster,’ per company materials — a characterisation that reflects internal ambition, not approved-product performance data. No head-to-head trial results against Dupixent have been disclosed in the available record, and clinical superiority has not been established.

Sam Fazeli, a Bloomberg Intelligence analyst, described the deal as enhancing AbbVie’s presence in dermatology by adding atopic dermatitis treatments to its portfolio, according to Bloomberg. The dosing-interval argument is a meaningful commercial hypothesis — patients and prescribers have demonstrated preference for less-frequent administration in other biologics categories — but payer formulary decisions will ultimately depend on comparative efficacy and cost data that do not yet exist in the public record.

Competitive position and who absorbs the pressure

The most direct incumbent under pressure is Dupixent, which works by blocking both interleukin-4 (IL-4) and IL-13 signalling, whereas zumilokibart targets IL-13 alone — a mechanistic distinction whose clinical relevance remains to be demonstrated in comparative trials. Dupixent’s commercial position in atopic dermatitis is substantial; the available record does not include a published revenue figure for Dupixent in the feeds, and most published figures on Dupixent’s sales trace to Sanofi and Regeneron’s own disclosures, which are not reproduced here.

AbbVie’s existing immunology portfolio also creates an internal dynamic worth noting. Skyrizi holds a 75% in-play capture rate among IL-23 drugs in the frontline inflammatory bowel disease (IBD) setting, per AbbVie chief commercial officer Jeffrey Stewart on the company’s earnings call, as reported by Fierce Pharma. The Apogee acquisition therefore extends AbbVie’s immunology surface into dermatology and respiratory indications where Skyrizi and Rinvoq have limited or no approved label — it is an expansion of addressable indication, not a defence of existing share.

The broader M&A context reinforces the deal’s scale. According to BioPharma Dive data, 32 biopharma acquisitions with at least $50 million in guaranteed upfront payments had been struck in 2026 as of the announcement date, with around two-thirds valued at $1 billion or more and six exceeding $5 billion — a pace described by BioPharma Dive as on track to surpass every year since at least 2020. The Apogee transaction sits at the upper end of that distribution.

The principal counterargument is clinical, not financial. Zumilokibart has not yet reached a regulatory filing, and the path from a dosing-convenience hypothesis to a formulary-preferred position in a market already served by an entrenched, well-reimbursed biologic is long. Payers covering Dupixent have established prior-authorisation pathways, step-therapy requirements, and rebate arrangements that a new entrant — regardless of dosing interval — will need to displace. AbbVie’s own guidance for 2026 adjusted diluted earnings per share of $13.87 to $14.07, per a company statement, reflects an expected $0.46 per-share dilution from the deal in 2027, according to stockti.com — a near-term earnings drag that the company is absorbing on the expectation of long-dated pipeline returns.

On the regulatory and geographic pathway, the announcement does not specify whether filings have been submitted to the U.S. Food and Drug Administration (FDA) or to non-U.S. regulators. No filings with Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA), Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), or Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) have been disclosed in the available record. For any of those markets, the applicable pathway would be a standard new biological entity registration, potentially with reliance on a recognised foreign authority decision once an FDA or European Medicines Agency (EMA) approval exists — a sequence that places Latin American access several years downstream of a U.S. approval that has not yet been sought.

Medicare and commercial payer coverage terms for zumilokibart have not been disclosed, as the drug has not reached approval. AbbVie’s existing immunology drugs — including Humira’s successor products — are subject to ongoing Medicare drug price negotiations; Linzess and Vraylar were among the 15 drugs targeted in the most recent negotiation cycle, per Reuters, though those negotiations concern different products and do not directly affect zumilokibart’s eventual pricing trajectory.

The acquisition’s deepest structural bet is that dosing convenience, not mechanism, will be the decisive formulary argument in a market where Dupixent’s clinical record is extensive and its rebate position is entrenched. AbbVie is wagering that the same patient-preference logic that drove long-acting formulations in other therapeutic categories will replicate in immunology — a thesis that the clinical data will either confirm or foreclose before the decade is out.